PDF
ePub
Citation
Print
INTRODUCTION
Chronic metabolic diseases, such as obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome (MS), dyslipidemia, and so on, are major causative factors for cardiovascular diseases. Among them, T2DM is a group of metabolic diseases characterized by hyperglycemia resulting from insulin resistance and insulin insufficiency. The affected population of T2DM is still increasing and the current treatment strategies may not enough to prevent vascular complications satisfactory. Insulin resistance is a major pathophysiological feature of T2DM, MS and obesity, and also associated with chronic inflammation, oxidative stress, endoplasmic reticulum (ER) stress, and cytokine production [1].
Heat shock (HS) is one of the major organismal and cellular stressors. Life form responds to HS in order to adapt environmental alterations. In 1962, Ritossa [2] identified the formation of a new chromosomal puffing pattern, which means transcriptional activation, against HS. This modification induces heat shock proteins (HSPs) synthesis in order to encounter cellular stress stimuli, such as HS, hypothermia, hypoxia, ischemia, heavy metal, ethanol, ultraviolet radiation, viral infection, and so on. The expression of HSP72 in T2MD is attenuated, and activation of heat shock response (HSR) confers benefits to improve lipid accumulation in liver and adipose tissue, inflammatory signals and insulin resistance, leading to metabolic ameliorations in diabetic rodents [3,4,5,6,7,8], monkey [9], and possibly in humans [10,11].
In this review, we focus on the relationship between HSR activation and chronic inflammation, insulin resistance, metabolic profiles in MS and T2DM. More importantly, we explore the benefits of novel treatment modality with a combination of HS and mild electrical stimulation (MES) that activate HSR efficiently and may target other molecules, providing new insights into physical medicine.
THE EFFECTS OF HSR ACTIVATION ON DIABETIC MODEL MICE
Mild electrical stimulation with hyperthermia
We found that activation of HSR using mild electric current with specific pulse wave and frequency in heat stimulation of 42 degrees, maximally induced HSP72, which is a major HSR product to exert HSR effects. HSP72 acts as a molecular chaperone to restrain the formation of abnormal protein aggregation, and controls protein transportation, cell death, chronic inflammation to protect cells from various kinds of stresses [12].
It has been reported that the expression of HSP72 was decreased in T2DM patients having insulin resistance, and that insulin resistance and glucose metabolism were both improved when HSP72 restored by various kinds of methods, such as HSP72 transgenic [4], HSP72 inducer administration [5,9,13] or long-term hyperthermia [6,7,11]. Our method (mild electrical stimulation with hyperthermia, MET) reduced fasting plasma glucose (Fig. 1A), insulin levels, insulin resistance (Fig. 1C), the amount of visceral adiposity, hepatic steatosis (Fig. 1D), and chronic inflammatory cytokines, with amelioration of insulin signaling (Fig. 1F, G) and whole body glucose homeostasis (Fig. 1B, E) in mice models of T2DM [8,14].
This MET also protects pancreatic β-cells from high glucose and cellular stresses, such as ER stress or oxidative stress [14]. When MIN6 cells are treated with tumor necrosis factor α (TNF-α), one of the stress kinase, c-jun N-terminal kinase (JNK) was activated (phosphorylated). This was largely eliminated using MET accompanied by attenuation of ER stress markers and cell death signals in TNF-α stimulated MIN6 cells (Fig. 2A). In insulin resistance with insulin deficient db/db mice, MET also exerts antidiabetic (Fig. 2B, C) and antiapoptotic effects in pancreatic β-cells with HSP72 induction, insulin and PDX-1 enhancement (Fig. 2D-H) [14]. The reinforcement of HSP72 in pancreatic β-cells may protect cells from apoptotic events and maintain the β-cell mass in diabetic patients.
HSP72 inducer geranylgeranyl acetone
Besides MET, a HSP72 inducible medication, geranylgeranyl acetone (GGA) can be used to activate HSR. Antigastric ulcer drug, GGA (Fig. 3A) was developed in Japan (generic name: teprenone) and is widely used in clinic. It is identified that gastric mucosa protection effect by GGA depends on HSP72 expression.
When a high-fat fed diabetes model mouse was given GGA orally every day in 200 mg/kg/day, the metabolic and pathophysiological effects appeared to be quite similar to MET treatment including weight reduction, reduced visceral fat accumulation, improvement of insulin resistance and glucose tolerance (Fig. 3B, C), and reduction in chronic inflammation [3].
GGA administration induced HSP72 mainly in liver (Fig. 3D), reduced visceral adipocyte size (Fig. 3H), improved insulin resistance and JNK activation (Fig. 3E). Hepatic gluconeogenic enzymes, such as phosphoenolpyruvate carboxykinase or glucose 6-phosphatase mRNA levels were both decreased by GGA treatment (Fig. 3F, G) [3]. These observations indirectly prove that MET improves body composition and glucose metabolism abnormality mainly through HSP72 induction.
THE EFFECTS OF HSR ACTIVATION ON HUMANS
Normal subjects
We performed the safe confirmation trial employing normal subjects before applying MET to life style related diseases in humans with MS or T2DM (Fig. 4). MET device specifically designed for humans produces electrical stimulation of 1.4±0.1 V/cm: the pads were positioned on the front and back of the abdomen, 55 pulses per second, 0.1 millisecond duration with 42℃ heat. The padded area was 15 cm in length×25 cm in width.
The harm phenomenon was not recognized without affecting the body composition, glucose metabolism and insulin resistance as expected, but the inflammatory markers in the normal range level showed a significant reduction, unexpectedly [10]. This physiologic significance was unidentified, but it is possible that MET is an effective anti-inflammatory intervention to alleviate low-level chronic inflammation and may contribute to decrease arteriosclerosis risk in the long term.
MS subjects
Clinical trial to investigate the effects of MET on MS was performed. Forty of eligible MS male subjects were randomly assigned into two groups; group I, a 12-week intervention period of MET followed by 12 weeks with no treatment; or group II, the reversed order. During the MET-treatment period, subjects were instructed to use MET 4 times a week for 60 minutes per session.
Visceral adipose volume measured by abdominal computed tomography scan and waist circumference was reduced, whereas body weight and subcutaneous adipose volume were not. Both systolic and diastolic blood pressures were significantly reduced. Fasting blood glucose and fasting insulin levels were both decreased. HbA1c showed a trend of reduction, but could not reach significance. As glucose and insulin levels were reduced, homeostatic model assessment of insulin resistance, quantitative insulin sensitivity check index, and composite whole body insulin sensitivity index were all significantly improved, and insulinogenic index was significantly decreased. Inflammatory cytokines or adipokines, such as high sensitivity C-reactive protein, adiponectin, leptin, and TNF-α, were all improved. In addition with those beneficial results, the count of white blood cells and low densitiy lipoprotein cholesterol were decreased (Fig. 4).
The mechanisms in reduction of visceral adiposity may be due to activation of 5' AMP-activated protein kinase (AMPK), upregulation of peroxisome proliferator-activated receptor coactivator-1α with increased mitochondrial density, JNK inhibition and/or muscle hypertrophy via nuclear factor of activated T-cell signal activation.
Inactivation of JNK and inhibition of nuclear factor-κB (NF-κB) nuclear translocation may contribute to attenuate chronic inflammation.
T2DM patients
Similar protocol was employed to investigate the MET effects in 40 of obese T2DM patients. Almost similar beneficial results were obtained with significant reduction of HbA1c in this cohort. Decrease of urinary albumin excretion and improvement of lipid profiles were observed (Fig. 4). As MET exerts antidiabetic, antiobesity effects as well as anti-inflammatory effect, this method may contribute to decrease the risk of atherogenic complications, such as brain infarction or ischemic heart disease.
THE MECHANISMS OF MET EFFECTS ON METABLIC DISEASES
Given that the combination of warm temperature and MES is administered to abdominal area, it is possible that abdominal organs, including liver, visceral fat, pancreatic islets and/or intestine are very likely to be targets. In mouse models, suppression of hepatic gluconeogenesis and reduction of visceral adiposity were both apparent.
A great number of humoral factors in blood circulation or neurotransmitters interact from one organ to another. Thus, interorgan crosstalk may regulate whole body glucose homeostasis. Then, we focused on circulating monocytes, which may reflect systemic inflammatory status.
To identify the effects of MET on the inflammatory milieu in vivo, CD14 positive circulating monocytes were isolated and levels of cytokine expression were examined. After 4 weeks of MET treatment, HSP72 protein and phosphorylation of AMPK in monocytes significantly increased. Phospho-JNK and lipopolysaccharide (LPS)-stimulated NF-κB p65 nuclear translocation was attenuated. Quantitative measurements of mRNA expression after LPS stimulation for C-reactive protein, interleukin-6, NF-κB, and TNF-α showed a significant reduction. These results clearly indicate that one of the target tissues of MET treatment is monocytes; however, it is also possible that other solid organs such as liver, adipose tissues and pancreas, may be targets as well. We cannot exclude the possibility that the changes in monocytes character might be secondary following amelioration of glucose metabolism.
CONCLUSIONS
One of the distinctive features of our method is using MES, which is specifically designed to act on human body, but not causing muscle contraction. It has been reported that a certain mild electric current increases blood flow or enhances wound healing [15]. Our collaborators group identified a particular mild electric current (direct current, 1.4±0.1 V/cm between the pad distance, 55 pulses per second, 0.1 millisecond duration) significantly activates insulin receptor accumulation in lipid raft component [16], there by increasing Akt phosphoryration and enhance glucose uptake independent of insulin [17]. They also found that this current suppresses HSP72 protein proteosomal degradation to increase the protein levels of HSP72 [18]. Therefore, this combination of 42℃ heat and particular mild electrical current may maximize the HSR effects to improve metabolic abnormalities in life-style related diseases, such as MS or T2DM. As these mechanisms, including antidiabetic, antiobesity and anti-inflammatory signals [19], are completely different from present medical approaches, MET could be one of the novel therapeutic alternatives, which can be added on the current therapy to T2DM.
XML Download